HZNP Stock Overview
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Horizon Therapeutics Public Limited Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$115.60 |
| 52 Week High | US$115.70 |
| 52 Week Low | US$60.03 |
| Beta | 1.04 |
| 1 Month Change | 10.12% |
| 3 Month Change | 14.02% |
| 1 Year Change | 84.90% |
| 3 Year Change | 44.90% |
| 5 Year Change | 498.34% |
| Change since IPO | 1,163.39% |
Recent News & Updates
Recent updates
These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely
Nov 25
Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?
Nov 02Horizon pays HemoShear milestone payment under pact to develop gout therapies
Sep 21Horizon Therapeutics announces $500M buyback program
Sep 09Horizon Therapeutics to expand footprint in Ireland
Aug 29Is Horizon Therapeutics (NASDAQ:HZNP) A Risky Investment?
Aug 22Horizon Therapeutics: This Core Biotech Company Is On Sale
Aug 19Analyst Forecasts Just Became More Bearish On Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)
Aug 04Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?
Aug 02Horizon Therapeutics: Buy The Dip For Slightly Risky, Catalyst Driven Growth
Jul 31Horizon gets FDA approval for Krystexxa's use with methotrexate for uncontrolled gout
Jul 08Horizon Therapeutics (NASDAQ:HZNP) Has A Rock Solid Balance Sheet
May 20Horizon: For Those Who Dare
May 09Here's Why I Think Horizon Therapeutics (NASDAQ:HZNP) Might Deserve Your Attention Today
May 02Shareholder Returns
| HZNP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.3% | -0.5% | -1.5% |
| 1Y | 84.9% | 10.8% | 13.8% |
Return vs Industry: HZNP exceeded the US Biotechs industry which returned 8.8% over the past year.
Return vs Market: HZNP exceeded the US Market which returned 12.9% over the past year.
Price Volatility
| HZNP volatility | |
|---|---|
| HZNP Average Weekly Movement | 2.0% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in US Market | 14.3% |
| 10% least volatile stocks in US Market | 2.5% |
Stable Share Price: HZNP is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: HZNP's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 2,190 | Tim Walbert | https://www.horizontherapeutics.com |
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use.
Horizon Therapeutics Public Limited Company Fundamentals Summary
| HZNP fundamental statistics | |
|---|---|
| Market Cap | US$26.47b |
| Earnings (TTM) | US$438.00m |
| Revenue (TTM) | US$3.64b |
60.4x
P/E Ratio7.3x
P/S RatioIs HZNP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HZNP income statement (TTM) | |
|---|---|
| Revenue | US$3.64b |
| Cost of Revenue | US$824.98m |
| Gross Profit | US$2.82b |
| Other Expenses | US$2.38b |
| Earnings | US$438.00m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.91 |
| Gross Margin | 77.36% |
| Net Profit Margin | 12.02% |
| Debt/Equity Ratio | 48.2% |
How did HZNP perform over the long term?
See historical performance and comparison